

Prevalence of Aminoglycoside Resistance Genes in *Acinetobacter baumannii* Isolates

Katayun Aliakbarzade¹; Safar Farajnia^{2,*}; Ashraf Karimi Nik¹; Farzaneh Zarei³; Asghar Tanomand⁴

¹Department of Microbiology, Science and Research Branch, Islamic Azad University of Kerman, IR Iran

²Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran

³Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran

⁴Tuberculosis and Lung Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran

*Corresponding author: Safar Farajnia, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran. Tel: +98 -9143018589 Fax: +98-4113363231, E-mail: farajnia@tbzmed.ac.ir

Received: June 09, 2013; Revised: August 05, 2013; Accepted: September 10, 2013

Background: *Acinetobacter baumannii* is one of the major causes of nosocomial infections and is resistant to most available antibiotics. Aminoglycosides remain as drugs of choice for treatment of *Acinetobacter* infections yet resistance to aminoglycosides has increased in the recent years.

Objectives: The present study investigated the prevalence of genes encoding aminoglycoside-modifying enzymes in *A. baumannii* strains isolated from patients of Tabriz city, northwest of Iran.

Materials and Methods: A total of 103 *Acinetobacter* isolates were collected from Imam Reza Hospital of Tabriz University of medical sciences. Antimicrobial susceptibility patterns of the isolates to different antimicrobial agents including cephalosporins, gentamicin, amikacin, tobramycin, colistin and polymyxin, were evaluated by the disc diffusion method. The frequency of aminoglycoside modifying enzymes encoding genes aacC1, aphA6, aadA1 and aadB was analyzed by the PCR method.

Results: Antimicrobial susceptibility analysis showed that the highest resistance was towards beta-lactam antibiotics including cephalosporins whereas the highest sensitivity was observed towards colistin (77%) and polymyxin (84%). The resistance rate to aminoglycosides was 81%, 86% and 63% for amikacin, gentamicin and tobramycin, respectively. The PCR results showed that among the 103 *A. baumannii* isolates, 56 (65.11%) were positive for aacC1, 52 (60.46%) for aphA6, 24 (27.9%) for aadA1 and 16 (18.6%) for aadB resistant genes.

Conclusions: The results of this study indicated that the genes encoding aminoglycoside-modifying enzymes are prevalent in *A. baumannii* isolates in the study region, which highlighted the necessity of considering preventive measures to control dissemination of these resistance genes.

Keywords: *Acinetobacter Baumannii*; Antimicrobial Agents; Aminoglycoside

1. Background

Acinetobacter baumannii is a Gram-negative, aerobic, non-motile, non-fastidious strictly aerobic and glucose-non-fermenting bacterium that has coccobacillary morphology on non-selective agar and is classified as an opportunistic pathogen in hospitals. This bacterium is commonly found in soil, water and sewage. It was experimentally shown that the majority of *A. baumannii* strains survive longer than *Escherichia coli* on dry surfaces, and some strains survive for more than four months. These characteristics are beneficial for the organism to survive in hospital environments and cause infection. *A. baumannii* has been recognized as the most important cause of nosocomial infections in immunocompromised patients particularly those in the intensive care units (ICUs) (1), and is ranked second after *Pseudomonas aeruginosa* among gram-negative nosocomial pathogens (2).

A. baumannii is the causative agent of several types of infections including bloodstream infections, ventilator-as-

sociated pneumonia, skin and soft tissue infections, meningitis and urinary tract infections (3). This bacterium can survive on different medical equipments and even on healthy human skin (4). *A. baumannii* is resistant to most available antibiotics and there are increasing reports of multidrug-resistant *A. baumannii* (MDRAB) outbreaks in clinical settings worldwide (5). Multidrug-resistant *A. baumannii* strains are resistant to at least three different classes of antimicrobial agents mainly beta-lactams, aminoglycosides, carbapenems and fluoroquinolones (6).

Aminoglycosides show various characteristics that make them useful for antimicrobial therapy. The bactericidal activity of aminoglycosides depend more on their concentration than on the duration of bacterial exposure to inhibitory concentrations of the antibiotics. The potential of aminoglycosides to kill bacteria depends on the concentration of the antibiotic, and increases with increasing concentrations. In addition, aminoglycosides

continue to kill bacteria even after the aminoglycoside is detectable, exhibiting an important post-antibiotic effect. This is probably due to a strong, irreversible binding to the ribosome. These drugs attack the bacteria in a two-step process; firstly, uptake of aminoglycosides into the bacteria takes place, which is an important process for their biological activity, and secondly, inside the bacterial cell the aminoglycoside binds to the ribosome and inhibits protein synthesis. Therefore, aminoglycosides represent an important group of antibiotics in treating different bacterial infections. However, in the recent years different resistance mechanisms have emerged against these antimicrobial agents.

Extended spectrum beta lactamases (ESBLs) are a class of group A beta lactamases which hydrolyze first, second and third generation cephalosporines but are inhibited by beta-lactamase inhibitors like clavulanic acid (7-9). The most prevalent resistance mechanisms to carbapenem antibiotics in *A. baumannii* is production of OXA-type β -lactamases (10, 11), and resistance to quinolones is related to alterations in the target enzymes, GyrA and ParC. Aminoglycosides have long been used for the treatment of *Acinetobacter* infections and still are an important alternative for therapy of infections caused by MDR strains. However, resistance to aminoglycosides has increased in the recent years in these bacteria (12).

The major mechanism of aminoglycoside resistance in clinical isolates of gram-negative bacteria is enzymatic modification of amino- or hydroxyl-groups of the aminoglycosides. Enzymatic modification of aminoglycosides results in reduced or abolished binding of the aminoglycoside molecule to the ribosome. Previous studies indicated that there are several mechanisms of resistance to aminoglycosides in the *Acinetobacter* spp. (13, 14). The most prevalent resistance mechanism is attributed to enzymatic inactivation by acetyltransferases (AAC), nucleotidyl transferases (ANT) and (phosphotransferases) APH (13). Many of the aminoglycoside modifying enzymes (AME) results in clinical resistance, but in general only the APHs and AACs produce high levels of resistance.

2. Objectives

The aim of this study was to evaluate the prevalence of aminoglycoside resistance and frequency of aacC1, aphA6, aadA1 and aadB aminoglycoside resistance genes among *A. baumannii* strains isolated from patients referred to Imam Reza hospital of Tabriz city.

3. Materials and Methods

3.1. Bacterial Isolation and Identification

In this study a total of 103 clinical *A. baumannii* strains were collected from hospitalized patients at Imam Reza Hospital of Tabriz University of Medical Sciences. The isolates were from different clinical samples including tra-

cheal secretion, bronchial lavage, blood, wound, sputum and urine. The samples were transferred to the laboratory of the Department of Microbiology in the medicine faculty and all isolates were identified by using standard biochemical tests such as, Gram staining, oxidase test, catalase test, motility, citrate utilization, oxidative/fermentative glucose (O/F) test and growth ability at 44°C (15). Species identification was confirmed by detection of blaOXA-51-like genes, as described previously (16).

3.2. Antimicrobial Susceptibility Test

The antimicrobial resistance of the isolates was determined by using the standard disk diffusion method according to the Clinical Laboratory Standard Institute (CLSI) guidelines (2011). Disk diffusion is a semi quantitative method used to examine bacterial susceptibility to specific antibiotics. It allows categorization of bacterial isolates as susceptible, intermediate or resistant to a variety of antimicrobial agents. The antimicrobial agents used in this study consisted of cefotaxime (30 μ g), cefixime (5 μ g), ceftizoxime (30 μ g), ceftazidime (30 μ g), ceftriaxone (30 μ g), cephalexin (30 μ g), cephalothin (30 μ g), tetracycline (30 μ g), ciprofloxacin (5 μ g), cotrimoxazole (25 μ g), ticarcillin (75 mg), polymyxin B (300 μ g), tobramycin (10 μ g), chloramphenicol (30 μ g), norfloxacin (10 μ g), ofloxacin (5 μ g), amikacin (30 μ g), gentamicin (10 μ g), ampicillin (10 μ g), carbenicillin (100 μ g), rifampin (5 μ g) and colistin (110 μ g) (MAST, Merseyside, UK). The isolates were cultured on Mueller Hinton Agar plates (Merck, Germany) inoculated with a bacterial suspension equal to 0.5 McFarland and incubated at 37°C for 18–24 hours. The diameter of the zone of growth inhibition was measured using the CLSI guidelines (16).

3.3. DNA Extraction and PCR Amplification

All *A. baumannii* isolates were grown for 18 hours at 37°C in MacConkey agar (Difco BD bioscience) and DNA were extracted by sodium dodecyl sulfate (SDS)-Proteinase K phenol chloroform method as described previously (17). Briefly, 4-5 fresh colonies were resuspended in 300 μ L of tris-EDTA (TE) buffer containing SDS (1%) and proteinase K (10 μ g/mL), and incubated at 40°C for 3 hours followed by phenol-chloroform extraction and ethanol precipitation. Several washing steps were performed, to improve the purity of the DNA. DNA was finally eluted in water and preserved at -20°C until use.

3.4. Detection of aminoglycoside-resistance genes

The genes encoding aminoglycoside-modifying enzymes, including phosphotransferases APH (3')-Via (aphA6), acetyltransferases AAC (3)-Ia (aacC1), nucleotidyl transferases ANT (2'')-Ia (aadB) and ANT(3'') -Ia (aadA1), were detected by PCR. Polymerase chain reaction (PCR) is a rapid method for in vitro amplification of DNA. The sequences of primers used in the PCR amplification are illustrated in Table 1.

Table 1. Primers Used for Detection of AME Genes (aphA6, aacC1, aadA1, aadB) in *A. baumannii*

Primer	Primer Sequences	Product Size, bp	Annealing Temperature, °C
aphA6 F	ATGGAATTGCCCAATATTATTC	797 bp	55
aphA6 R	TCAATTCAATTCATCAAGTTTAA		
aadA1 F	ATGAGGGAAGCGGTGATCG	792 bp	52
aadA1 R	TTATTGCGGACTACCTTGGTG		
aadB F	ATGGACACAACGCAGGTCCG	534 bp	55
aadB R	TTAGGCCGCATATCGCGACC		
aacC1 F	ATGGGCATCATTCGCACATGTAGG	456 bp	52
aacC1 R	TTAGGTGGCGGCTACTTGGGTC		

Table 2. Thermocycler Program for Amplification of Gene AphA6/aadB/aadA1/aacC1

NO.	Parameter Steps	Temperature, °C	Time
1	initial denaturation	95	3'
2	denaturation	94	1'
3	annealing	55/55/52/52	1'
4	cycle number	35	
5	extension	72	45"
6	final extension	72	5'

3.5. PCR Analysis

PCR reactions were performed in a final volume of 25 µL (24 µL PCR master mix plus 1 µL of template DNA). PCR amplification was carried out in a thermal cycler with the following parameters: initial denaturation at 95°C for 3 minutes, followed by 35 cycles of 60 seconds, denaturation at 94°C, 60 seconds for annealing at primers annealing temperatures (Table 1) and 45 seconds for extension at 72°C with a final extension at 72°C for 5 minutes (Table 2). The presence and sizes of amplicons were analyzed by electrophoresis on 1.2 % agarose gel in a tris-acetate-EDTA (TAE) buffer at 90 volts alongside a 1 Kb DNA ladder (Fermentas, Lithuania). Electrophoresis was performed for one hour and finally the gels were stained with ethidium bromide and visualized using the gel documentation system.

4. Results

4.1. Characteristics of the Study Population

The mean age of the population was 51 years, with a range of 14 to 86 years. The isolates were obtained from patients belonging to different age groups: 20–39 years (n = 26), 40–59 (n = 40), 60–90 years (n = 34) and three isolates were from patients less than 20 years old.

4.2. Isolates and Antimicrobial Susceptibility


A total of 103 *A. baumannii* isolates were recovered from clinical specimens of hospitalized patients that had been admitted to the Imam Reza Hospital of Tabriz, North-West of Iran. The isolates were obtained from invasive and non-invasive sites, including trachea (38%), urine (22%), sputum (10%), blood (7%), catheter (6%), bronchial washings

Table 3. Antimicrobial Resistance Pattern of *Acinetobacter Baumannii* Against Different Antibiotics

Antibiotics	Resistant, %	Intermediate, %	Sensitive, %
Ticarcillin	100	0	0
Cefixime	100	0	0
Ceftizoxime	100	0	0
Cephalexin	97	0	3
Cefotaxime	97	0	3
Ampicillin	94	0	6
Ceftriaxone	94	0	6
Ceftazidime	93	0	7
Cephalothin	91	0	9
Carbenicillin	89	0	11
Gentamicin	86	5	9
Cotrimoxazole	85	0	15
Norfloxacin	84	0	16
Amikacin	81	2	17
Ciprofloxacin	80	0	20
Chloramphenicol	78	0	22
Ofloxacin	71	0	29
Tetracycline	65	31	4
Tobramycin	63	0	37
Rifampin	27	0	73
Colistin	19	4	77
Polymyxin B	16	0	84


(6%), wound (5%), abscess drainage (3%), cerebrospinal fluid (2%), ascites fluid (2%) and pleural effusion (2%). The samples were transferred to the laboratory of the Microbiology Department of Tabriz University and were immediately inoculated on to MacConkey and blood agar plates. Analysis of antimicrobial susceptibility in this study showed that the highest resistance was against cefixime (100%), ceftizoxime (100%) and ticarcillin (100%), whereas the highest susceptibility was observed towards polymyxin B (84%), colistin (77%) and rifampin (73%) (Table 3). Resistance to various aminoglycosides was as follows; gentamicin 86%, tobramycin 63% and amikacin 81%. Tobramycin was the most active agent tested.

Figure 1. Amplification of aacC1 Resistance Gene by the PCR Technique



Lane 1 isolate negative for aacC1 gene, Lane 2-8 isolates with aacC1 gene, Lane 9, no DNA and Lane 10 related to size marker (1 kb DNA ladder).

Figure 2. Amplification of aphA6 Resistance Gene by the PCR Technique




Lane 1 and 7, isolates negative for aphA (6) gene, Lane 2_6 and 8, isolates with aphA (6) genes, Lane 9, size marker (1 kb DNA ladder).

4.3. Aminoglycoside-Modifying Enzymes

Screening of aminoglycoside resistant isolates for resistance genes by PCR (Figure 1 -4) revealed that the prevalence of the aacC1 gene, which confers resistance to amikacin and gentamicin, was 65.11%. Screening for aphA6, aadA1 and aadB genes revealed that 52 (60.46 %) isolates were positive for aphA6, 24 (27.9 %) for aadA1 and 16 (18.6 %) for aadB, respectively.


Twenty one resistant isolates (20.4 %) had no AME genes. Isolates with two AME genes were seen in 32 (31.06%) cases for aacC1 and aphA6, 17 (16.5%) cases for aadA1 and aphA6 genes, 15 (14.56%) cases for aacC1 and aadA1, 10 (9.7%) cases for aphA6 and aadB, 8 (7.76%) cases for aadA1 and aadB genes and 6 (5.82%) isolates had aacC1 and aadB genes.

Figure 3. PCR Amplification of aadA1 Resistance Gene



Lane 1,4,5 isolates negative for aadA1 gene, Lane 2, 3 and 6, isolates with aadA1 gene, Lane 7, no DNA and Lane 8 related to size marker (1 kb DNA ladder).

Figure 4. PCR Amplification of aadB Resistance Gene



Lane 1, 2, 7 and 8 isolates negative for aadB gene, Lane 3, 4, 5 and 6 isolates with aadB gene, Lane 9, no DNA and Lane 10 size marker (1 kb DNA ladder).

Nine isolates (8.73%) had three AME genes, *aacC1*, *aadA1* and *aphA6*. Three isolates were positive for *aacC1*, *aphA6* and *aadB*, and three isolates had a combination of four different AME genes including *aacC1*, *aphA6*, *aadB* and *aadA1*. Strains with *aacC1* or *aphA6* were found to be resistant to kanamycin and gentamicin or kanamycin and amikacin, respectively, while *aadB* was associated with resistance to kanamycin, gentamicin and tobramycin (18).

5. Discussion

MDR *A. baumannii* is an important pathogen that is involved in nosocomial infections especially in ICU wards. This bacterium is one of the most important problems encountered in hospitals, clinics and public health centers (19). This organism is very difficult to eradicate due to its inherent and acquired resistance against multiple classes of antibiotics, so that very few effective therapeutic options remain available. Aminoglycosides have been an important group of antibiotics in treatment of serious bacterial infections, especially those with aerobic Gram negative bacteria, but recent reports indicated the emergence of resistance to aminoglycosides in *Acinetobacter* isolates in different parts of the world. Aminoglycoside resistance in *Acinetobacter* primarily results from inactivation of the antibiotic by specific modifying enzymes such as acetyl transferases, phosphotransferases, and adenyl transferases.

This study focused on resistance to different aminoglycosides in clinically important isolates of *A. baumannii*, with emphasis on gentamicin, tobramycin and amikacin. The prevalence of AMEs encoding genes were investigated in *A. baumannii* isolates recovered from patients hospitalized in Tabriz city in the North West of Iran. Findings of the present study showed that 65.11% of the studied *Acinetobacter* isolates were positive for *aacC1* genes. This indicates a high prevalence of resistance due to *aacC1* gene in the studied cases. Also other aminoglycoside-modifying enzyme genes detected by PCR were *aphA6* (60.46 %), *aadA1* (27.9 %) and *aadB* (18.6 %). These results indicate that the rate of resistance by aminoglycoside-modifying enzyme types *aphA6*, *aadA1* and *aadB* have increased significantly over the past years.

Moniri et al. (20) evaluated antimicrobial susceptibility and aminoglycoside resistance genes of sixty *Acinetobacter* strains isolated from hospitalized patients in Kashan city. They reported the presence of acetyltransferase genes (*aacC1*) in 63.3% of *Acinetobacter* isolates. Other genes including phosphotransferase (*aphA6*) and adenyl transferase (*aadA1* and *aadB*) were detected in 65%, 41.7% and 3.3%, of the isolates, respectively. In our study the prevalence of *aphA6* and *aadA1* genes was much lower than that reported from Kashan city but the prevalence of *aadB* genes was significantly higher in our study. These findings showed that clinical isolates of *Acinetobacter* in hospitals carry various kinds of aminoglycoside resistance genes. Also, *Acinetobacter* isolates in the study of Moniri et al. from Kashan city showed the highest resis-

tance rate against amikacin, tobramycin and ceftazidim, respectively; while isolated bacteria were more sensitive to ampicillic/subactam. The resistance rates reported for amikacin and tobramycin were 80% and 68.3%, respectively. There is little difference between our findings and this study. In our study the resistance rate to amikacin was 81% and tobramycin 63%. Another study in Iran was done by Shahcheraghi and his colleagues in Tehran (21), which showed the highest resistance (100%) to cefixime that was very similar to our study. The lowest resistance was reported against colistin (4.2 %) whereas in our study, 19% of isolates were resistant to colistin (21).

In a study done by Lee and his colleagues in Korea in 2011 (12), the majority of aminoglycoside-modifying enzyme genes detected by PCR were *aacC1* (56%), *aadB* (48%), and *aphA6* (71%) (12). Nemeč and his colleagues in Czech Republic in 2004 investigated the diversity of genes encoding aminoglycoside-modifying enzymes and their association with class 1 integrons in *A. baumannii* and reported aminoglycoside resistance genes in 95 % of isolates: *aacC1* (n = 68), *aadA1* (n = 68), *aphA6* (n = 55), and *aadB* (n = 31) (18). The rate of resistance in our study was considerably higher than the rates found for other geographical regions including Korea and Czech Republic.

Akers et al. (22) in 2010 studied the susceptibility of 107 isolates of *A. baumannii*-calcoaceticus complex to amikacin, gentamicin and tobramycin using the disk diffusion method. The susceptibility to aminoglycoside antibiotics were reported 96.6% to gentamicin and 77.5% to tobramycin. In the Akers study, 56.1% of isolates contained two and 3.7% contained three AME genes. In our study resistance to gentamicin and tobramycin were 86 % and 63%, respectively. In the present study, isolates with two AME genes were seen in 32 (31.06%) cases for *aacC1* and *aphA6*; 17 (16.5%) cases for *aadA1* and *aphA6* genes; 15 (14.56%) cases for *aacC1* and *aadA1*; 10 (9.7%) cases for *aphA6* and *aadB*; 8 (7.76%) cases for *aadA1* and *aadB* genes and 6 (5.82%) isolates had *aacC1* and *aadB* genes. These results are in agreement with some other studies that have found that *aacC1* and *aphA6* genes are the most common AME genes in *A. baumannii* isolates. Lee et al. and Moniri et al. (12, 20) detected *aacC1* in 56% and 63.3 % of isolates, respectively. In another study that was done by Nigro et al. (23) in Australia they investigated the pattern of resistance to aminoglycosides in sixty-one multi-resistant *A. baumannii* strains isolated between 2000 and 2010 in six Australian hospitals. In this work the isolates were screened for AME genes; *aadB*, *aacC1*, *aphA1b*, *aphA6* and OXA 23 beta-lactamase gene (20). They found that the *aphA6* gene was present in combination with *aacC1* and *aphA1* in two isolates.

Our study results showed a remarkable diversity of genes encoding aminoglycoside-modifying enzymes in the study region. The multiple resistance mechanisms in *A. baumannii* isolates make this bacterium a major clinical and public health concern. Resistance of these bacteria to commercially available drugs subsequently makes their therapy extremely difficult. Our study results indi-

cated that the genes related to AME are prevalent in the *A. baumannii* strains in the study region which highlighted the necessity of considering preventive measure to control dissemination of resistance genes (21).

Acknowledgements

The authors like to thank Dr. Paymani and Dr. Sohrabi for their technical assistance and providing some of isolates for this work.

Authors' Contributions

Study concept and design: Dr. Safar Farajnia. Performing experiments: Katayun Aliakbarzade. Analysis and interpretation of data: Dr. Safar Farajnia. Drafting of the manuscript: Katayun Aliakbarzade and Safar Farajnia. Critical revision of the manuscript: Safar Farajnia and Ashraf Karimi Nik. Statistical analysis: Asghar Tanomand and Farzaneh Zarei.

Funding/Support

This study was supported in part by a grant from the research deputy of Tabriz University of Medical Sciences.

References

- Dinc U, Bayramoglu G, Buruk K, Ulusoy H, Tosun I, Kaklikkaya N. Molecular epidemiology of *Acinetobacter baumannii*-*Acinetobacter calcoaceticus* complex isolated from clinical specimens at an intensive care unit. *Saudi Med J*. 2010;**31**(4):453-5.
- Berlau J, Aucken H, Malnick H, Pitt T. Distribution of *Acinetobacter* species on skin of healthy humans. *Eur J Clin Microbiol Infect Dis*. 1999;**18**(3):179-83.
- Fournier PE, Riche H. The epidemiology and control of *Acinetobacter baumannii* in health care facilities. *Clin Infect Dis*. 2006;**42**(5):692-9.
- Murray PR, Baron EJ. *Manual of Clinical Microbiology*. Washington: ASM Press; 2007.
- Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a successful pathogen. *Clin Microbiol Rev*. 2008;**21**(3):538-82.
- Huang LY, Chen TL, Lu PL, Tsai CA, Cho WL, Chang FY, et al. Dissemination of multidrug-resistant, class 1 integron-carrying *Acinetobacter baumannii* isolates in Taiwan. *Clin Microbiol Infect*. 2008;**14**(11):1010-9.
- Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin Microbiol Rev*. 2001;**14**(4):933-51.
- Jacoby GA, Munoz-Price LS. The new beta-lactamases. *N Engl J Med*. 2005;**352**(4):380-91.
- Gniadkowski M. Evolution and epidemiology of extended-spectrum beta-lactamases (ESBLs) and ESBL-producing microorganisms. *Clin Microbiol Infect*. 2001;**7**(11):597-608.
- Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother*. 2007;**51**(10):3471-84.
- Poirel L, Nordmann P. Carbapenem resistance in *Acinetobacter baumannii*: mechanisms and epidemiology. *Clin Microbiol Infect*. 2006;**12**(9):826-36.
- Lee K, Yong D, Jeong SH, Chong Y. Multidrug-resistant *Acinetobacter* spp.: increasingly problematic nosocomial pathogens. *Yonsei Med J*. 2011;**52**(6):879-91.
- Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. *Microbiol Rev*. 1993;**57**(1):138-63.
- Miller GH, Sabatelli FJ, Naples L, Hare RS, Shaw KJ. The most frequently occurring aminoglycoside resistance mechanisms-combined results of surveys in eight regions of the world. The Aminoglycoside Resistance Study Groups. *J Chemother*. 1995;**7 Suppl 2**:17-30.
- Feizabadi MM, Fathollahzadeh B, Taherikalani M, Rasoolinejad M, Sadeghifard N, Aligholi M, et al. Antimicrobial susceptibility patterns and distribution of blaOXA genes among *Acinetobacter* spp. Isolated from patients at Tehran hospitals. *Jpn J Infect Dis*. 2008;**61**(4):274-8.
- Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of *Acinetobacter baumannii* by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. *J Clin Microbiol*. 2006;**44**(8):2974-6.
- Yousefi S, Farajnia S, Nahaei MR, Akhi MT, Ghotaslou R, Soroush MH, et al. Detection of metallo-beta-lactamase-encoding genes among clinical isolates of *Pseudomonas aeruginosa* in north-west of Iran. *Diagn Microbiol Infect Dis*. 2010;**68**(3):322-5.
- Nemec A, Dolzani L, Brisse S, van den Broek P, Dijkshoorn L. Diversity of aminoglycoside-resistance genes and their association with class 1 integrons among strains of pan-European *Acinetobacter baumannii* clones. *J Med Microbiol*. 2004;**53**(Pt 12):1233-40.
- Farajnia S, Azhari F, Alikhani MY, Hosseini MK, Peymani A, Sohrabi N. Prevalence of PER and VEB Type Extended Spectrum Betalactamases among Multidrug Resistant *Acinetobacter baumannii* Isolates in North-West of Iran. *Iran J Basic Med Sci*. 2013;**16**(6):751-5.
- Moniri R, Farahani RK, Shajari G, Shirazi MN, Ghasemi A. Molecular epidemiology of aminoglycosides resistance in *Acinetobacter* spp. With emergence of multidrug-resistant strains. *Iran J Public Health*. 2010;**39**(2):63-8.
- Shahcheraghi F, Abbasalipour M, Feizabadi M, Ebrahimipour G, Akbari N. Isolation and genetic characterization of metallo-beta-lactamase and carbapenemase producing strains of *Acinetobacter baumannii* from patients at Tehran hospitals. *Iran J Microbiol*. 2011;**3**(2):68-74.
- Akers KS, Chaney C, Barsoumian A, Beckius M, Zera W, Yu X, et al. Aminoglycoside resistance and susceptibility testing errors in *Acinetobacter baumannii*-calcoaceticus complex. *J Clin Microbiol*. 2010;**48**(4):1132-8.
- Nigro SJ, Post V, Hall RM. Aminoglycoside resistance in multiply antibiotic-resistant *Acinetobacter baumannii* belonging to global clone 2 from Australian hospitals. *J Antimicrob Chemother*. 2011;**66**(7):1504-9.